Mean (SD) demographic characteristics at entry
| Part I | Part II | |||
|---|---|---|---|---|
| BUD800+EF (n=332) | BUD800+PL (n=331) | BUD400+EF (n=250) | BUD400+PL (n=255) | |
| NA=not applicable. | ||||
| Sex (M/F) | 137/195 | 143/188 | 97/153 | 108/147 |
| Age (y) | 38.9 (16.7) | 37.7 (16.1) | 37.2 (16.0) | 38.3 (16.7) |
| Weight (kg) | 73.3 (17.5) | 74.2 (17.0) | 74.0 (17.1) | 72.8 (17.0) |
| Height (cm) | 167.0 (10.1) | 167.4 (9.7) | 166.8 (9.3) | 167.3 (9.9) |
| Treatment during part I eformoterol/placebo | NA | NA | 145/105 | 131/124 |
| Asthma history: time since diagnosis, n (%) | ||||
| <1 year | 28 (8) | 19 (6) | 17 (7) | 16 (6) |
| 1–5 years | 83 (25) | 63 (19) | 52 (21) | 54 (21) |
| > 5 years | 221 (67) | 249 (75) | 181 (72) | 185 (73) |
| Steroid use before entry, n (%) | 223 (67) | 223 (67) | 164 (66) | 177 (69) |
| Pre-study inhaled steroid: n (%) | ||||
| Beclomethasone | 182 (82) | 185 (83) | 129 (79) | 155 (88) |
| Budesonide | 37 (17) | 31 (14) | 30 (18) | 19 (11) |
| Fluticasone | 4 (2) | 7 (3) | 5 (3) | 3 (2) |
| Pre-study inhaled steroid dose (μg/day) | 368.7 (162.6) | 348.7 (110.8) | 356.4 (142.7) | 359.9 (137.3) |
| Baseline lung function (l/min) | ||||
| Entry PEF | 385.2 (90.7) | 384.7 (90.9) | NA | NA |
| % predicted PEF | 74.2 (12.6) | 73.8 (13.5) | ||
| Randomisation to part I | ||||
| PEF | 402.2 (94.8) | 404.1 (93.5) | NA | NA |
| % predicted PEF | 77.6 (13.3) | 77.6 (14.1) | ||
| Randomisation to part II | ||||
| PEF | NA | NA | 441.2 (106.7) | 439.6 (101.7) |
| % predicted PEF | 85.3 (14.8) | 84.5 (14.0) | ||